Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?

Robert Izquierdo, The Motley Fool

Sat, July 4, 2026 astatine 3:31 PM CDT 4 min read

The VanEck Pharmaceutical ETF (NASDAQ:PPH) offers a much cost-efficient introduction constituent and higher income potential, portion the Invesco Pharmaceuticals ETF (NYSEMKT:PJP) has precocious demonstrated stronger terms appreciation for investors seeking assemblage momentum.

These exchange-traded funds some people the U.S. pharmaceutical space, but they disagree importantly successful their operation and outgo structures. While some funds seizure the manufacture absorption connected cause improvement and research, their varying attraction levels and fees tin pb to diverging outcomes for semipermanent shareholders.

Snapshot (cost & size)

Beta measures terms volatility comparative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr instrumentality represents full instrumentality implicit the trailing 12 months. Dividend output is the trailing-12-month organisation yield.

The VanEck money is the much affordable prime with a 0.36% disbursal ratio, redeeming investors 0.21 percent points compared to the Invesco fund. It besides provides a higher dividend payout for income-oriented portfolios, which whitethorn assistance offset immoderate of the volatility inherent successful the healthcare sector.

Performance & hazard examination

What's wrong

The VanEck Pharmaceutical ETF focuses exclusively connected the healthcare assemblage with 26 holdings, seeking to replicate the MVIS US Listed Pharmaceutical 25 Index. Its largest positions see Eli Lilly & Co (NYSE:LLY) astatine 20.24%, Novartis (NYSE:NVS) astatine 10.63%, and Merck & Co (NYSE:MRK) astatine 9.85%. It was launched successful 2011. The VanEck Pharmaceutical ETF has paid $2.15 per stock implicit the trailing 12 months, which connected its caller ~$109.35 stock terms works retired to a 2.00% yield.

The Invesco Pharmaceuticals ETF besides maintains 100% healthcare vulnerability but spreads its superior crossed 29 holdings done a non-diversified approach. Its largest positions see Eli Lilly & Co astatine 5.22%, Abbott Laboratories (NYSE:ABT) astatine 5.16%, and AbbVie (NYSE:ABBV) astatine 5.14%. It was launched successful 2005. Invesco Pharmaceuticals ETF has paid $1.06 per stock implicit the trailing 12 months, which connected its caller ~$118.45 stock terms works retired to a 0.90% yield.

For much guidance connected ETF investing, cheque retired the afloat usher astatine this link.